• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

Inherited Bleeding Disorders Literature

F1000 Medical Research Posters

View information about CSL Behring posters presented at scientific symposia about Recombinant Factor Therapies.
Learn more

Presented here is a variety of books and articles of interest to healthcare professionals in the area of coagulation and bleeding disorders. Topics include Hemophilia A, Hemophilia B, VWD, Hemophilia A /B with Inhibitors and Other Hemophilia articles.

Hemophilia A

The story of a unique molecule in hemophilia A: recombinant single-chain factor VIII.
Pabinger-Fasching I. Thromb Res. 2016;141(Suppl 3):S2–S4. Available on ScienceDirect.

Bringing new therapy options to the hemophilia community
Bensen-Kennedy D. Thromb Res. 2013;131(Suppl 2):S15–8. Available on Pubmed.

Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII
Zollner S, et al. Thromb Res. 2013;132:280-287. E-print

Non-clinical pharmacokinetics and pharmacodynamics of rVIII­SingleChain, a novel recombinant single-chain factor VIII
Zollner S, et al. Thromb Res. 2014;134:125–31. Available on ScienceDirect.

Hemophilia B

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
Santagostino, E, et al. 2016; 127(14). Available on Blood.

Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats
Herzog E, et al. Thromb Res. 2014;133:900–7. Available on ScienceDirect.

Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B
Uri Martinowitz, Aaron Lubetsky Thrombosis Research 131S2 (2013) S11–S14 E-print

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX
Metzner HJ, et al. Thromb Haemost. 2009;102:634–44. Available on Pubmed.

VWD

Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).
Abshire TC. Et al. Haemophilia. 2013 Jan;19(1):76-81. doi: 10.1111/j.1365-2516.2012.02916.x. Epub 2012 Jul 23. PDF (118kb)

von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group. J Thromb Haemost. 2007 Jul;5(7):1420-30. Epub 2007 Apr 16. PDF (685kb)

von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M Haemophilia. 2011 Nov;17(6):895-905. doi: 10.1111/j.1365-2516.2011.02534.x. Epub 2011 Apr 27. Available on Pubmed.

Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
Schramm W. Haemophilia. 2008 Nov;14 Suppl 5:3-10. doi: 10.1111/j.1365-2516.2008.01847.x. Available on Pubmed.

Hemophilia A /B with Inhibitors

Use of Haemate® P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C. Haemophilia. 2013 Mar;19(2):281-6. doi: 10.1111/hae.12018. Epub 2012 Oct 8. PDF (127kb)

Factor VIII Products and Inhibitors in Severe Hemophilia A
Iorio A, Skinner M, Makris M. Letter to the Editor, New England Journal of Medicine 2013 April 11. PDF (333kb)

The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.
Kessler CM, Iorio A. Haemophilia. 2013 May;19(3):351-4. doi: 10.1111/hae.12149. Epub 2013 Apr 12. PDF (73kb)

Other Hemophilia

Von Willebrand Disease and Other Bleeding Disorders in Women Experiencing Menorrhagia or Postpartum Hemorrhage. An Observational Study on Postpartum Levels of von Willebrand Factor in Women with and without von Willebrand Disease: Rationale and Study Design.
James, Kouides, Abdul-Kadir, Edlund, Federici, Halimeh, Kamphuisen, Konkle, Martinez-Perez, McLintock, Peyvandi, and Winikoff. American Journal of Obstetrics & Gynecology 2009. Available on Elsevier.

Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz, U.; Luboshitz, J; Bashari, D.; Ravid, B.; Gorina, E.; Regan, L.; Stass, H.; and Lubetsky, A. Haemophilia (May, 2009), 15, 676–685. Available on Wiley Online Library.

100 Questions & Answers about von Willebrand Disease (2008)
James, Andra H., Jones & Bartlett Publishers Available from Amazon.

Aging with Hemophilia: Medical & Psychosocial Impact (2008)
Mauser-Bunschoten E.P., De Knecht-van Eekelen A., and Smit C. Available from World Federation of Hemophilia (WFH).

Sucrose-Formulated Octocog Alfa.
Frampton J.E. and Wagstaff A.J. Drugs 2008; 68 (6): 839-53. Available on Springer.

Comparative Analysis and Classification of von Willebrand Factor/Factor VIII Concentrates: Impact on Treatment of Patients with von Willebrand Disease.
Budde U. et al. Seminars in Thrombosis & Hemostasis 2006;32(6):626-635. doi: 10.1055/s-2006-949668 Available on Thieme E-Journals.


Last Updated: 7/6/2016 10:12 AM
  • E-mail
  • Print
  • Share